Anaphore raises $25 million in series A financing

Proceeds from the financing will be used to accelerate development of Atrimers, a new class of protein therapeutics that the company is developing to address significant unmet medical needs in immune-mediated diseases and oncology.

Atrimers are novel drug candidates engineered from a fully-human serum protein that is naturally secreted as a trimeric structure. Anaphore’s proprietary protein engineering platform TrimerX provides multiple approaches to generate
Atrimers, therapeutics with biological, manufacturing and commercial advantages over traditional drugs such as antibodies, smaller protein scaffolds, and small molecules.

Atrimers and the TrimerX platform are protected by significant intellectual property including over 13 patent families.

Katherine Bowdish, CEO of Anaphore, said: “This financing supports the work Anaphore has done to date on a validated and innovative platform that has great potential to generate a large number of products in multiple therapeutic areas.

“The funds take us out two years or more, depending on how much partnering we do. We believe the TrimerX platform has tremendous value and the Atrimers we develop will significantly improve patient outcomes in many critical diseases.”